Latest Conference Articles

Dr Prerakkumar Parikh Reacts to FDA Approvals for First Neurology, Tocilizumab Biosimilars

Brooke McCormick,Skylar Jeremias

January 7 2024

Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, reacts to recent FDA approvals for the first natalizumab and tocilizumab biosimilars.

Posters Show Efficacy for Combination Therapies With Trastuzumab Biosimilars in Breast Cancer

Skylar Jeremias

January 4 2024

Posters from San Antonio Breast Cancer Symposium 2023 found that combination therapies featuring trastuzumab biosimilars and other common cancer medicines were safe and effective in patients with breast cancer.

The Top 5 Most-Read Conference Stories of 2023

Skylar Jeremias

December 28 2023

The top 5 most-read conference stories of 2023 recapped some of big biosimilar takeaways from this year’s conferences, including insight into how geopolitics will impact the industry, efforts from government agencies, and strategies to increase biosimilar uptake.

Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry

Skylar Jeremias,Brooke McCormick

December 20 2023

At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.

SABCS Posters Evaluate Real-World Outcomes Associated With Ogivri

Skylar Jeremias

December 14 2023

Two Taiwanese posters presented at the San Antonio Breast Cancer Symposium (SABCS) 2023 annual meeting evaluated the real-world implications of using trastuzumab biosimilars, particularly Ogivri (trastuzumab-dkst) in patients with HER2-postive breast cancer.

Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces

Skylar Jeremias

November 13 2023

At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.

Commercial Biosimilar Coverage Is on the Rise, but Preferences Still Vary

Skylar Jeremias

October 28 2023

A poster from AMCP Nexus quantifies trends in biosimilar coverage within Tufts Medical Center, finding that payer coverage of these products has increased but individual preferences among payers still vary.

AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry

Skylar Jeremias

October 26 2023

Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.

Samsung Bioepis Presents Positive Phase 3 Data on Aflibercept Candidate

Skylar Jeremias

October 9 2023

At EURETINA 2023, Samsung Bioepis shared positive comparative efficacy data on its aflibercept biosimilar candidate, demonstrating that the product is as safe and effective as the originator (Eylea).

Abstracts Highlight Growing Comfortability With Trastuzumab Biosimilars in Breast Cancer

Skylar Jeremias

July 31 2023

Abstracts presented at the annual meeting of the American Society of Clinical Oncology (ASCO 2023) emphasized the safety and efficacy of a trastuzumab biosimilar in treating HER2-positive breast cancer and growing utilization of trastuzumab biosimilars over time.